BioSpace News Archive

Biotech Showcase™ 2020, to be held January 13–15, 2020, during the most important week in healthcare at the Hilton San Francisco Union Square.

Revive aims to build a portfolio of cannabinoid-based drugs for the treatment of rare inflammatory diseases with its initial focus on Autoimmune liver diseases

The non-surgical nose job is a little-known beauty savior promising natural, affordable and fast results without going under the knife.

Technavio has announced its latest market research report titled global Alzheimer’s disease therapeutics market 2020-2024.

BioSpace, the leader in life sciences news and careers, announced their NextGen Bio “Class of 2020,” a list of 21 up-and-coming life sciences companies in the United States.

Clinigen Group plc has partnered with Orphazyme A/S, a global biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, to introduce and administer an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C in the US.

Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced that senior executives will be speaking at two healthcare innovation and investor conferences in San Francisco.

BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today the appointment of Kevin Ostrander as Senior Vice President of Business Development and member of the Company Executive Leadership Team, effective today January 6

Gerard (Jerry) A. Vitti, president and CEO of Healthcare Financial Inc. (HFI), a firm that connects vulnerable populations with public benefit programs, will serve on the Editorial Advisory Council of FierceHealthcare, a digital platform that publishes top-notch content on a range of health-related verticals.

Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention Deficit Hyperactivity Disorder (“ADHD”), today announced the appointment of Mr. Dave Lemus as Chief Financial Officer and the promotion of Mr. Peter Lammers to the position of Chief Commercial Officer.